Synaptrix

Executive Summary

Synaptrix Labs is pioneering the intersection of neuroscience and artificial intelligence with its flagship product, Neuralis — the first device that enables paralyzed patients to control wheelchairs using only brain activity. Founded in 2020 and headquartered in San Francisco, the company leverages a proprietary AI-based EEG signal processing model to decode neural signals in real time, translating intention into movement. This breakthrough addresses the critical unmet need for mobility and independence among individuals with severe motor impairments, such as spinal cord injury or ALS. The technology promises to improve quality of life while reducing caregiver dependency, positioning Synaptrix at the forefront of brain-computer interface (BCI) applications for assistive mobility. As a private company with no disclosed funding or valuation, Synaptrix appears to be in an early development stage. Its pioneering approach faces significant technical and regulatory hurdles, including ensuring signal reliability, miniaturization, and clinical validation. However, the convergence of advances in AI, low-cost EEG sensors, and growing acceptance of neurotechnology could accelerate adoption. The total addressable market for powered wheelchairs and BCI systems is substantial, and Synaptrix's novel solution differentiates it from traditional assistive devices. Near-term success hinges on securing regulatory clearance, demonstrating clinical efficacy, and forming strategic partnerships with rehabilitation centers or medical device distributors.

Upcoming Catalysts (preview)

• Q4 2026FDA Breakthrough Device Designation for Neuralis80% success
• Q2 2027First-in-Human Clinical Trial Results60% success
• Q1 2027Strategic Partnership with Major Rehabilitation Hospital70% success